22 G - 25 G SINS Trial for Pancreatic Masses

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

352 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-07-28

Study Completion Date

2018-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

After patients have been screened and have signed informed consent, they will be taken to the endoscopy suite. Once the decision has been made to proceed with Fine Needle Aspiration (FNA), the subject will be randomized to 1 of 4 groups:

* 22 gauge (G) needle with suction
* 25 G needle with suction
* 22 G needle without suction
* 25 G needle without suction

Follow-up Phone Call Phase:

Unit staff will call patients 1 week after the procedure to check if patients had any adverse events from the procedure and this will be recorded onto the dataset.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Trial Comparing 19 and 25G Needles for Fine Needle Aspiration (FNA) of Solid Pancreatic Mass Lesions Greater Than 35mm

NCT01815606

Pancreatic Cancer

COMPLETED NA

Trial Comparing 19 and 25-gauge EUS-FNA Needles

NCT01677312

Cancer of Pancreas Pancreatic Neoplasm

COMPLETED NA

Comparing Biopsy Needles for Endoscopic Ultrasound Guided Samples for Pancreatic Masses

NCT02911974

Pancreatic Neoplasm

COMPLETED NA

Comparison of Two Fine Needle Biopsy Needles for Solid Pancreatic Masses

NCT02910960

Pancreatic Neoplasm

COMPLETED NA

Fine Needle Biopsy of Solid Pancreatic Mass Lesions

NCT04085055

Pancreatic Neoplasms

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All adult patients referred to Florida Hospital for evaluation of a pancreatic mass lesion will be eligible for entry into the study. Patients will be approached at the time of procedural consent for the study.

1. After written informed consent is taken, Endoscopic Ultrasound (EUS) will be performed under conscious sedation.
2. At the time of EUS, patients who require FNA will be randomized to the two needles (22 G or 25 G needles) and to the two techniques (using suction or not using suction).
3. Computer-generated randomization assignments using the block randomization method will be obtained from the statistician prior to study enrollment. These will be placed in sequentially numbered sealed opaque envelopes and opened by the endoscopy nurse immediately after the decision to perform FNA is made. The randomization sequence will specify the needle size to be used and whether or not suction will be applied for FNA.
4. FNA will be performed in the standard fashion using one of the designated needle sizes (using the fanning technique to pass the needle 12-16 times into the lesion) by one of the experienced endosonographers in the unit. The needle stylet will be left in place for the first pass and then removed for subsequent passes. Suction will be applied during aspiration of the mass as dictated by the randomization sequence.
5. First two passes will be performed to obtain tissue sample for cell block analysis. Therefore, the tissue obtained with the first and second passes will be expressed onto a slide and into test tubes for cell block analysis.
6. From the third pass onwards, the aspirate obtained will be examined onsite by the cytopathologist, who will be available to interpret the slides immediately to determine diagnostic adequacy of the sample per standard practice. Once the diagnosis is made and the adequacy of the sample is affirmed by the cytopathologist, the procedure will be stopped and the echoendoscope will be withdrawn from the patient.
7. Total number of passes to obtain a diagnostic cytological aspirate made will be recorded at the time of procedure, as well as the occurrence of needle dysfunction, technical failure, and any immediate complications.
8. The samples taken will be transported to the pathology lab (per standard practice) where the cellular aspirate and cell block samples will be evaluated by the pathologist. 10% of samples from each subgroup (i.e. 22G with suction, 22G without suction, 25G with suction, 25G without suction) will be further analyzed for the presence of molecular markers for malignancy.
9. After the appropriate observations are deemed satisfactory, patients will be discharged as per unit policy.
10. Unit staff will call patients 1 week after the procedure to check if patients had any adverse events from the procedure and this will be recorded onto the dataset.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

22 gauge with suction

EUS-FNA of pancreatic masses will be performed with a 22 gauge needle using suction.

Group Type ACTIVE_COMPARATOR

EUS-FNA of pancreatic masses

Intervention Type PROCEDURE

EUS-FNA of pancreatic masses will be performed using a 22 or a 25 gauge needle with or without applying suction.

22 gauge needle

Intervention Type DEVICE

22 gauge without suction

EUS-FNA of pancreatic masses will be performed with a 22 gauge needle without suction.

Group Type ACTIVE_COMPARATOR

EUS-FNA of pancreatic masses

Intervention Type PROCEDURE

EUS-FNA of pancreatic masses will be performed using a 22 or a 25 gauge needle with or without applying suction.

22 gauge needle

Intervention Type DEVICE

25 gauge with suction

EUS-FNA of pancreatic masses will be performed with a 25 gauge needle using suction.

Group Type ACTIVE_COMPARATOR

EUS-FNA of pancreatic masses

Intervention Type PROCEDURE

EUS-FNA of pancreatic masses will be performed using a 22 or a 25 gauge needle with or without applying suction.

25 gauge needle

Intervention Type DEVICE

25 gauge without suction

EUS-FNA of pancreatic masses will be performed with a 25 gauge needle without suction.

Group Type ACTIVE_COMPARATOR

EUS-FNA of pancreatic masses

Intervention Type PROCEDURE

EUS-FNA of pancreatic masses will be performed using a 22 or a 25 gauge needle with or without applying suction.

25 gauge needle

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EUS-FNA of pancreatic masses

EUS-FNA of pancreatic masses will be performed using a 22 or a 25 gauge needle with or without applying suction.

Intervention Type PROCEDURE

22 gauge needle

Intervention Type DEVICE

25 gauge needle

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. All patients referred to Florida Hospital Endoscopy Unit for assessment of pancreatic mass lesions that require FNA
2. Age ≥ 19 years

Exclusion Criteria

1. Age \<19 years
2. Unable to safely undergo EUS for any reason
3. Coagulopathy (INR \>1.6, Thrombocytopenia with platelet count \<80,000/ml)
4. Unable to provide consent for any reason
5. Pregnancy (confirmed with Standard of Care urine pregnancy test for all women with child-bearing potential)

Minimum Eligible Age

19 Years

Maximum Eligible Age

89 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes